X
    X
    X
    X

    Edwards Wildman's Sharon Blinkoff Authors Article on the FCPA as the Greatest Pharmaceutical Executive Risk in Pharmaceutical Compliance Monitor

    News
    Sharon Blinkoff, counsel in the firm's Business Law Department in New York, wrote an article about how the Department of Justice has increased Foreign Corrupt Practices Act (FCPA) enforcement efforts, with particular emphasis on pharmaceutical and biotech industries in Pharmaceutical Compliance Monitor. In the article, "Greatest Pharmaceutical Executive Risk: DOJ and the Foreign Corrupt Practices Act," the authors analyzed risks unique to pharmaceutical and biotech companies, potential penalties and recent examples, and FCPA compliance basics.

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.